NYSEConsumer StaplesTobaccoSnapshot 2026-08-31
Reading PM? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Warn: Primary pillar under pressure — Adjusted diluted EPS growth excluding currency: EPS growth ~5.5% vs 9% target.
Philip Morris grows smoke-free products fast, with 43% of revenue in Q1 2026. Adjusted EPS rose 16% in Q1 and full-year growth is guided at 9% to 11%. Capital spending stays disciplined at $1.5 billion, focused on smoke-free business.
Growth in smoke-free products may slow or face regulatory hurdles. Capital allocation could be pressured by impairments. EPS growth may fall short of 9% to 11% guidance amid currency or market headwinds.
The price is about 13% above our fair value near $165, reflecting roughly 7% revenue growth expected by analysts. Our fair value is below the Street median, indicating some caution versus more optimistic views.
Breaks if: adjusted diluted EPS growth excluding currency falls below 7% in 2026-FY
Target adjusted diluted EPS growth of 9% to 11% excluding currency effects, supported by operational improvements and product mix.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on smoke-free products. The current thesis state is stable, supported by consistent revenue growth and management's commitment to key priorities.
The market seems to have priced in a low level of fragility due to weak execution quality, but not the full extent of potential challenges. The valuation is characterized as justified, with a slight expectations gap indicating that the market does not anticipate significant surprises.
Fundamentals are likely to continue showing strong performance, with management on track to achieve its revenue and earnings growth targets. However, there is a moderate risk of missing expectations, given recent industry trends.
The thesis hinges on macroeconomic factors such as job growth and inflation trends. Additionally, any potential guidance cuts in future earnings calls could negatively impact sentiment.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this view. The company announced a contract manufacturing agreement with Altria. This deal may improve operational efficiency for PM. Analysts have raised their price targets for PM. This reflects a generally positive outlook despite some currency challenges.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Management stated this priority in all 6 quarters from 2025-Q1 through 2026-Q2. The company forecasted adjusted diluted EPS excluding currency to increase between 7.5% and 9.5% in 2026, consistent with prior guidance of 9% to 11% growth excluding currency in 2025. Adjusted diluted EPS excluding currency grew from $3.60 in the first half of 2025 to $3.94 in the first half of 2026, showing progress aligned with the target. The trajectory is delivering consistent EPS growth excluding currency.
“Adjusted diluted EPS excluding currency projected to increase 7.5% to 9.5% in 2026 forecast.”
“Adjusted diluted EPS excluding currency projected to increase 7.5% to 9.5% in 2026 forecast.”
“Adjusted diluted EPS growth of 9.5% to 11.5% excluding currency stated in 2025 guidance.”
“Adjusted diluted EPS growth of 9% to 11% excluding currency reiterated.”
“Adjusted diluted EPS growth of 9% to 11% excluding currency stated.”
“Adjusted diluted EPS growth of 9% to 11% excluding currency forecasted.”
Breaks if: CAPEX falls outside $1.4 to $1.6 billion range or shifts away from smoke-free focus in 2026-FY
Sustain disciplined capital expenditure within $1.4 to $1.6 billion annually, predominantly supporting investments in the smoke-free product business.
Management stated this priority in all 6 quarters from 2025-Q1 through 2026-Q2. Capital expenditures have been consistently forecasted within the $1.4 to $1.6 billion range, predominantly supporting the smoke-free business. This is consistent with prior years' actuals and guidance, reflecting disciplined capital allocation focused on growth areas. The trajectory is stable and aligned with management's stated capital expenditure discipline.
“Capital expenditures of $1.4 to $1.6 billion, predominantly supporting the smoke-free business.”
“Capital expenditures of $1.4 to $1.6 billion, predominantly supporting the smoke-free business.”
“Capital expenditures of around $1.6 billion, almost entirely due to investments supporting the smoke-free business.”
“Capital expenditures of around $1.6 billion, almost entirely due to investments supporting the smoke-free business.”
“Capital expenditures of around $1.6 billion, almost entirely due to investments supporting the smoke-free business.”
“Capital expenditures of around $1.5 billion, including further investments in ZYN capacity in the U.S.”
Breaks if: organic net revenue growth falls below 4% in 2026-FY
Breaks if: YoY smoke-free shipment volume growth falls below 10% in 2026-FY
Continue expanding and innovating the smoke-free product portfolio including IQOS, ZYN, and VEEV to drive volume, revenue, and market share growth globally.
Stated as a priority in all 6 quarters from 2025-Q1 through 2026-Q2. The smoke-free business shipment volume grew from 14.4% in 2025-Q1 to 7.5% in 2026-Q2, with IQOS maintaining around 75% volume share in 2026-Q2. ZYN expanded from 44 markets in 2025-Q1 to 60 markets in 2026-Q2, and VEEV shipments increased by 55.1% in 2026-Q2. The trajectory shows consistent delivery of volume and market expansion aligned with management's stated growth focus.
“Smoke-free business shipment volume up 7.5%, IQOS leading with ~75% volume share, ZYN in 60 markets, VEEV shipments up 55.1%.”
“Smoke-free business net revenue growth 12.4%, IQOS surpassing Marlboro, ZYN shipments growing 10%, VEEV profitable growth.”
“Smoke-free business shipment volumes up 12.8%, IQOS volume share ~76%, ZYN in 55 markets, VEEV doubled shipments.”
“Smoke-free business shipment volumes up 16.6%, IQOS volume share ~76%, ZYN growing 39% offtake, VEEV shipment volumes up 91%.”
“Smoke-free business shipment volumes up 11.8%, IQOS volume share ~76%, ZYN offtake growth ~36%, VEEV shipments doubled.”
“Smoke-free business shipment volumes up 14.4%, IQOS volume share ~77%, ZYN shipments exceeded 200 million cans, VEEV shipments more than doubled.”
Overall, PM's performance and strategic focus suggest a stable outlook for the next 1 to 3 years. Not investment advice.
